Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

EBioMedicine

Volumn 7, Issue , 2016, Pages 112-120

  Wewer Albrechtsen, Nicolai J ^a,b,c,d   Hornburg, Daniel ^c   Albrechtsen, Reidar ^a,e   Svendsen, Berit ^a,b   Toräng, Signe ^a,b   Jepsen, Sara L ^a,b   Kuhre, Rune E ^a,b   Hansen, Marie ^a,b   Janus, Charlotte ^a,b   Floyd, Andrea ^f   Lund, Asger ^b,f   Vilsbøll, Tina ^f   Knop, Filip K ^a,b,f   Vestergaard, Henrik ^b   Deacon, Carolyn F ^a,b   Meissner, Felix ^c   Mann, Matthias ^c,d   Holst, Jens J ^a,b   Hartmann, Bolette ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d University of Copenhagen   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GLP 1; Gut hormones; Low abundant peptides; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; GLICENTIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN;

ANIMAL TISSUE; ARTICLE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE RELEASE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; STOMACH BYPASS; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; GASTRIC BYPASS SURGERY; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES;

ANIMALS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MASS SPECTROMETRY; MICE; OXYNTOMODULIN; PROTEOMICS;

EID: 84962406909     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.03.034     Document Type: Article

References (45)

1. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422(6928):198-207.
2. Bagger J.I., Holst J.J., Hartmann B., Andersen B., Knop F.K., Vilsboll T. Effect of oxyntomodulin, glucagon, GLP-1 and combined glucagon + GLP-1 infusion on food intake, appetite and resting energy expenditure. J. Clin. Endocrinol. Metab. 2015, (p. jc20152335).
3. Baldissera F.G., Holst J.J., Knuhtsen S., Hilsted L., Nielsen O.V. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 1988, 21(1-2):151-166.
4. Bonfils P.K., Taskiran M., Damgaard M., Goetze J.P., Floyd A.K., Funch-Jensen P., Kristiansen V.B., Stockel M., Bouchelouche P.N., Gadsboll N. Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase In mid-regional pro-atrial natriuretic peptide in morbid obese patients. J. Hypertens. 2015, 33(6):1215-1225.
5. Bouillon R., Drucker D.J., Ferrannini E., Grinspoon S., Rosen C.J., Zimmet P. The past 10 years - new hormones, new functions, new endocrine organs. Nat. Rev. Endocrinol. 2015, (vol. advance online publication).
6. Calanna S., Christensen M., Holst J.J., Laferrère B., Gluud L.L., Vilsbøll T., Knop F.K. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013, 56(5):965-972.
7. Cohen M.A., Ellis S.M., le Roux C.W., Batterham R.L., Park A., Patterson M., Frost G.S., Ghatei M.A., Bloom S.R. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 2003, 88(10):4696-4701.
8. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26(12):1367-1372.
9. Færch K., Torekov S.S., johansen N.B., Witte R., Jonsson A.E., Pedersen O., Hansen T., Lauritzen T.A.S., JJ Holst, Vistisen D., M.E., J Reduced release of GLP-1 in subgroups of prediabetes and type 2 diabetes. Diabetes 2014, 1748-P.
10. Færch K., Torekov S.S., Vistisen D., Johansen N.B., Witte D.R., Jonsson A., Pedersen O., Hansen T., Lauritzen T., Sandbæk A., Holst J.J., Jørgensen M.E. Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: the ADDITION-PRO study. Diabetes 2015.
11. Fonslow B.R., Carvalho P.C., Academia K., Freeby S., Xu T., Nakorchevsky A., Paulus A., Yates J.R. Improvements In proteomic metrics of low abundance proteins through proteome equalization using ProteoMiner prior to MudPIT. J. Proteome Res. 2011, 10(8):3690-3700.
12. Gillette M.A., Carr S.A. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 2013, 10(1):28-34.
13. Gillette M.A., Carr S.A. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 2013, 10(1):28-34.
14. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140(11):5356-5363.
15. Hartmann B., VH, Bonfils P., Hansen M., Wewer, Albrechtsen N.J., EP, Floyd A., Svenningsen A., Holst J.J. The effect of gastric bypass treatment for obesity on hormones related to bone re-modeling and intestinal growth. Eur. Calcif. Tissue Soc. Lissabon 2013, 1:111.
16. Hjollund, KR, Deacon, CF & Holst, JJ 2011, 'Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs', paper presented to Diabetologia, 2011, <>. doi:10.1007/s00125-011-2168-7.
17. Holst J.J. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr. Opin. Pharmacol. 2013.
18. Holst J.J. Incretin hormones and the satiation signal. Int. J. Obes. (Lond) 2013, 37(9):1161-1168.
19. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6(12):2212-2229.
20. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6(12):2212-2229.
21. Kuhre R.E., Albrechtsen N.J.W., Hartmann B., Deacon C.F., Holst J.J. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. J. Diabetes Complications 2014.
22. Kuhre R.E., Albrechtsen N.W., Windelov J.A., Svendsen B., Hartmann B., Holst J.J. GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides 2014, 55:52-57.
23. Kulak N.A., Pichler G., Paron I., Nagaraj N., Mann M. Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat. Methods 2014, 11(3):319-324.
24. Lee A.Y.H., Chappell D.L., Bak M.J., Judo M., Liang L., Churakova T., Ayanoglu G., Castro-Perez J., Zhou H., Previs S., Souza S.C., Lassman M.E., Laterza O.F. Multiplexed quantification of proglucagon-derived peptides by immunoaffinity enrichment and tandem mass Spectrometry after a meal tolerance test. Clin. Chem. 2015.
25. Lin B., White J.T., Wu J., Lele S., Old L.J., Hood L., Odunsi K. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin. Appl. 2009, 3(7):853-861.
26. Madsbad S., Dirksen C., Holst J.J. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014, 2(2):152-164.
27. Madsbad S., Holst J.J. GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 2014, 63(10):3172-3174.
28. Mann M., Kulak N., Nagaraj N., Cox Jr The coming age of complete, accurate, and ubiquitous proteomes. Mol. Cell 2013, 49(4):583-590.
29. Meier J.J., Nauck M.A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function?. Diabetes 2010, 59(5):1117-1125.
30. Meissner F., Scheltema R.A., Mollenkopf H.J., Mann M. Direct proteomic quantification of the secretome of activated immune cells. Science 2013, 340(6131):475-478.
31. Meng R., Gormley M., Bhat V.B., Rosenberg A., Quong A.A. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J. Proteomics 2011, 75(2):366-374.
32. Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) In type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54(1):10-18.
33. Olsen J.V., Macek B., Lange O., Makarov A., Horning S., Mann M. Higher-energy C-trap dissociation for peptide modification analysis. Nat. Methods 2007, 4(9):709-712.
34. Parker C.E., Borchers C.H. Mass spectrometry based biomarker discovery, verification, and validation - quality assurance and control of protein biomarker assays. Mol. Oncol. 2014, 8(4):840-858.
35. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol. Metab. 2014, 3(3):241-251.
36. Rappsilber J., Mann M., Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2007, 2(8):1896-1906.
37. Rhee N.A., Wahlgren C.D., Pedersen J., Mortensen B., Langholz E., Wandall E.P., Friis S.U., Vilmann P., Paulsen S.J., Kristiansen V.B., Jelsing J., Dalbøge L.S., Poulsen S.S., Holst J.J., Vilsbøll T., Knop F.K. Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia 2015, 58(10):2254-2258.
38. Sadry S.A., Drucker D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 2013, 9(7):425-433.
39. Sandoval D.A., D'Alessio D.A. Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease 2015, 95.
40. Scheltema R.A., Hauschild J.-P., Lange O., Hornburg D., Denisov E., Damoc E., Kuehn A., Makarov A., Mann M. The Q exactive HF, a benchtop mass spectrometer with a pre-filter, high-performance quadrupole and an ultra-high-field orbitrap analyzer. Mol. Cell. Proteomics 2014, 13(12):3698-3708.
41. Schjoldager B.T., Baldissera F.G., Mortensen P.E., Holst J.J., Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and Insulin secretion in man. Eur. J. Clin. Invest. 1988, 18(5):499-503.
42. Surinova S., Schiess R., Hüttenhain R., Cerciello F., Wollscheid B., Aebersold R. On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10(1):5-16.
43. Svendsen B., Pais R., Engelstoft M.S., Milev N.B., Richards P., Christiansen C.B., Egerod K.L., Jensen S.M., Habib A.M., Gribble F.M., Schwartz T.W., Reimann F., Holst J.J. GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness. J. Endocrinol. 2016, 228(1):39-48.
44. Wewer Albrechtsen N.J., Bak M.J., Hartmann B., Christensen L.W., Kuhre R.E., Deacon C., Holst J.J. Stability of glucagon-like peptide-1 and glucagon in human plasma. Endocr. Connect. 2015.
45. Wewer Albrechtsen N.J., Kuhre R.E., Deacon C.F., Holst J.J. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert. Rev. Endocrinol. Metab 2014, 9(01):61-72.